Drug Discovery Unchained: What The Drug!? #2

webinar

Wed, 14 Aug 2024, 16:00 CEST (Berlin)

Dr. Alexander Neumann, BioSolveIT, Germany

Drug Discovery Unchained: What The Drug!? #2

What happens when somebody asks you to do drug discovery? No preparation, no script, no nothing. Just live performing and sharing your thoughts.

This is “What The Drug!?”: a live session tackling a drug discovery challenge using BioSolveIT tools, with the aim of reaching a conclusion in a reasonable time frame. What is the challenge? We do not know. Everything will be revealed during the stream, and we will see how things unfold.

The first session was a good starting point, but let’s see how things develop. Dive into the session, discuss together, and explore on-the-fly compound design.

Current news

What's So Special About The 'Activity Spotter'? Detailed Insights Into SeeSAR's New Mode
April 29, 2026 10:22 CEST
SeeSAR’s Activity Spotter Mode is designed to dismantle the barrier of raw data and actionable SAR. It helps to answer the most relevant fields in hit-to-lead and lead optimization campaigns: 3D SAR and pharmacophore modeling. Which structural features in my molecule set are associated with activity? Which ones are linked...
Read on
Tool of the Month - FlexX
April 29, 2026 08:53 CEST
Spring is Molecular Docking Season The bread and butter of computational chemistry: predicting potential binding modes, which serves as a crucial foundation for SAR analysis and design decisions, is being made available to everyone this month with the proprietary docking tool FlexX. Validated by over 10,000 citations of its original...
Read on
The 95 Billion Update: Access the REAL Space
April 9, 2026 13:57 CEST
The latest update of Enamine’s REAL Space brings a new expansion, now featuring over 94.5 billion accessible, drug-like products, approaching the 100 billion mark. Built from 173 curated reaction protocols and 202,620 in-stock reagents and building blocks based on Enamine’s in-house knowledge, this version further enhances the world’s largest commercially...
Read on